These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 20385979)

  • 1. EpCAM as a target in cancer therapy.
    Gires O; Bauerle PA
    J Clin Oncol; 2010 May; 28(15):e239-40; author reply e241-2. PubMed ID: 20385979
    [No Abstract]   [Full Text] [Related]  

  • 2. [EpCAM a proteolytically cleaved oncogene and an excellent therapeutic target in cancer].
    Gires O
    Med Sci (Paris); 2009 May; 25(5):449-50. PubMed ID: 19480822
    [No Abstract]   [Full Text] [Related]  

  • 3. Adecatumumab: an anti-EpCAM monoclonal antibody, from the bench to the bedside.
    Kurtz JE; Dufour P
    Expert Opin Biol Ther; 2010 Jun; 10(6):951-8. PubMed ID: 20426706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical effects of a chimeric anti-EpCAM monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal carcinoma.
    Liljefors M; Nilsson B; Fagerberg J; Ragnhammar P; Mellstedt H; Frödin JE
    Int J Oncol; 2005 Jun; 26(6):1581-9. PubMed ID: 15870873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Letter to the editor: efficacy and safety of anti-Trop antibodies, R. Cubas, M. Li, C. Chen and Q. Yao, Biochim Biophys Acta 1796 (2009) 309-1.
    Trerotola M; Guerra E; Alberti S
    Biochim Biophys Acta; 2010 Apr; 1805(2):119-20; author reply 121-2. PubMed ID: 20079406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective gene transfer into primary human gastric tumors using epithelial cell adhesion molecule-targeted adenoviral vectors with ablated native tropism.
    Heideman DA; van Beusechem VW; Offerhaus GJ; Wickham TJ; Roelvink PW; Craanen ME; Pinedo HM; Meijer CJ; Gerritsen WR
    Hum Gene Ther; 2002 Sep; 13(14):1677-85. PubMed ID: 12396621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-EpCAM monoclonal antibody (MAb17-1A) based treatment combined with alpha-interferon, 5-fluorouracil and granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal carcinoma.
    Liljefors M; Ragnhammar P; Nilsson B; Ullenhag G; Mellstedt H; Frödin JE
    Int J Oncol; 2004 Sep; 25(3):703-11. PubMed ID: 15289873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epithelial cell adhesion molecule-targeted drug delivery for cancer therapy.
    Simon M; Stefan N; Plückthun A; Zangemeister-Wittke U
    Expert Opin Drug Deliv; 2013 Apr; 10(4):451-68. PubMed ID: 23316711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug evaluation: adecatumumab, an engineered human anti-EpCAM antibody.
    Kirman I; Whelan RL
    Curr Opin Mol Ther; 2007 Apr; 9(2):190-6. PubMed ID: 17458174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Targeted cancer drugs and their development].
    Kaje-Reinikainen S
    Duodecim; 2005; 121(2):189; author reply 189. PubMed ID: 15745358
    [No Abstract]   [Full Text] [Related]  

  • 11. The developing trend of monoclonal antibodies in the treatment of colorectal cancer.
    Elfiky AA; Saif MW
    Expert Opin Biol Ther; 2007 Jun; 7(6):871-83. PubMed ID: 17555372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy.
    Osta WA; Chen Y; Mikhitarian K; Mitas M; Salem M; Hannun YA; Cole DJ; Gillanders WE
    Cancer Res; 2004 Aug; 64(16):5818-24. PubMed ID: 15313925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug evaluation: IGN-101--an anti-EpCAM murine antibody vaccine for cancer.
    Kirman I
    Curr Opin Mol Ther; 2006 Aug; 8(4):358-65. PubMed ID: 16955700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trop molecules as targets for anti-tumor immunotherapy in man.
    Alberti S
    Tumori; 2001; 87(6):S5-8. PubMed ID: 11989616
    [No Abstract]   [Full Text] [Related]  

  • 15. Monoclonal antibody therapy with edrecolomab in breast cancer patients: monitoring of elimination of disseminated cytokeratin-positive tumor cells in bone marrow.
    Braun S; Hepp F; Kentenich CR; Janni W; Pantel K; Riethmüller G; Willgeroth F; Sommer HL
    Clin Cancer Res; 1999 Dec; 5(12):3999-4004. PubMed ID: 10632331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The EpCAM high/CD44 high colorectal carcinoma stem cell phenotype is not preferentially expressed in tumour buds.
    Prall F; Maletzki C; Linnebacher M
    Histopathology; 2010 Mar; 56(4):553-5. PubMed ID: 20459564
    [No Abstract]   [Full Text] [Related]  

  • 17. Lysis of cancer cells by autologous T cells in breast cancer pleural effusates treated with anti-EpCAM BiTE antibody MT110.
    Witthauer J; Schlereth B; Brischwein K; Winter H; Funke I; Jauch KW; Baeuerle P; Mayer B
    Breast Cancer Res Treat; 2009 Oct; 117(3):471-81. PubMed ID: 18819003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EpCAM an immunotherapeutic target for gastrointestinal malignancy: current experience and future challenges.
    Chaudry MA; Sales K; Ruf P; Lindhofer H; Winslet MC
    Br J Cancer; 2007 Apr; 96(7):1013-9. PubMed ID: 17325709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A complex of EpCAM, claudin-7, CD44 variant isoforms, and tetraspanins promotes colorectal cancer progression.
    Kuhn S; Koch M; Nübel T; Ladwein M; Antolovic D; Klingbeil P; Hildebrand D; Moldenhauer G; Langbein L; Franke WW; Weitz J; Zöller M
    Mol Cancer Res; 2007 Jun; 5(6):553-67. PubMed ID: 17579117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Panitumumab: a new frontier of target therapy for the treatment of metastatic colorectal cancer.
    Addeo R; Caraglia M; Cerbone D; Frega N; Cimmino G; Abbruzzese A; Del Prete S
    Expert Rev Anticancer Ther; 2010 Apr; 10(4):499-505. PubMed ID: 20397915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.